Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) fell 3.9% during trading on Wednesday . The stock traded as low as $15.51 and last traded at $15.64, with a volume of 328,998 shares changing hands. The stock had previously closed at $16.28.

Separately, Zacks Investment Research upgraded shares of Dynavax Technologies Corp. from a “sell” rating to a “hold” rating in a research report on Monday, June 27th.

The stock’s market cap is $602.86 million. The stock’s 50-day moving average is $15.65 and its 200 day moving average is $16.80.

Dynavax Technologies Corp. (NASDAQ:DVAX) last issued its quarterly earnings data on Friday, August 5th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by $0.07. The business had revenue of $2.65 million for the quarter, compared to the consensus estimate of $1.58 million. During the same period last year, the business earned ($0.80) earnings per share. The firm’s quarterly revenue was up 70.8% compared to the same quarter last year. Equities analysts anticipate that Dynavax Technologies Corp. will post ($2.96) earnings per share for the current fiscal year.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.